Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisArun J. Sanyal, Patricia R. Robuck, Mark L. Van Natta et al.|New England Journal of Medicine|2010Cited by 3.3k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trialBrent A. Neuschwander‐Tetri, Edward Doo, Rohit Loomba et al.|The Lancet|2014Cited by 2.2k
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver DiseaseArun J. Sanyal, James Tonascia, Mark L. Van Natta et al.|New England Journal of Medicine|2021Cited by 1.1k
Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver DiseaseMohammad Shadab Siddiqui, Arun J. Sanyal, Raj Vuppalanchi et al.|Clinical Gastroenterology and Hepatology|2018Cited by 593
Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithmsTinsay A. Woreta, Arun J. Sanyal, Mark L. Van Natta et al.|PLoS ONE|2022Cited by 43